Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.

Ruan Z, Ung COL, Shen Y, Zhang Y, Wang W, Luo J, Zou H, Xue Y, Wang Y, Hu H, Guo L

Diabetes therapy : research, treatment and education of diabetes and related disorders8 Aug 2022Cited by 10 (Europe PMC)

PMID35934763PMCIDPMC9500126DOI10.1007/s13300-022-01301-4PepBankPUB-35934763

Read at source PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese diabetes model, semaglutide 0.5 mg increased projected discounted life expectancy versus dulaglutide 1.5 mg.
In plain wordsIn computer projections, lower-dose semaglutide increased life expectancy compared with dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseDiscounted life expectancy, lower semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Life expectancy improvement
0.04 years
semaglutide 0.5 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3593476301
02Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese diabetes model, semaglutide 1.0 mg increased projected discounted life expectancy versus dulaglutide 1.5 mg.
In plain wordsIn computer projections, higher-dose semaglutide increased life expectancy compared with dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseDiscounted life expectancy, higher semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Life expectancy improvement
0.1 years
semaglutide 1.0 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3593476302
03Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese diabetes model, semaglutide 0.5 mg increased projected discounted quality-adjusted life expectancy versus dulaglutide 1.5 mg.
In plain wordsIn computer projections, lower-dose semaglutide increased quality-adjusted life expectancy compared with dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseDiscounted quality-adjusted life expectancy, lower semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Quality-adjusted life expectancy improvement
0.08 QALYs
semaglutide 0.5 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3593476303
04Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese diabetes model, semaglutide 1.0 mg increased projected discounted quality-adjusted life expectancy versus dulaglutide 1.5 mg.
In plain wordsIn computer projections, higher-dose semaglutide increased quality-adjusted life expectancy compared with dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseDiscounted quality-adjusted life expectancy, higher semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Quality-adjusted life expectancy improvement
0.19 QALYs
semaglutide 1.0 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3593476304
05Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese diabetes model, semaglutide 0.5 mg reduced projected lifetime costs versus dulaglutide.
In plain wordsIn computer projections, lower-dose semaglutide reduced lifetime costs compared with dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseLifetime costs, lower semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Lifetime cost savings
8355 CNY
semaglutide 0.5 mg versus dulaglutide
Source sentences
Summary
Clinical benefits were achieved at reduced costs, with lifetime cost savings of 8355 Chinese Yuan (CNY) with once-weekly semaglutide 0.5 mg and 11,553 CNY with once-weekly semaglutide 1.0 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3593476305
06Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Chinese diabetes model, semaglutide 1.0 mg reduced projected lifetime costs by 11,553 CNY versus dulaglutide.
In plain wordsIn computer projections, higher-dose semaglutide reduced lifetime costs compared with dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseLifetime costs, higher semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Dulaglutide 1.5 mg
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
Clinical benefits were achieved at reduced costs, with lifetime cost savings of 8355 Chinese Yuan (CNY) with once-weekly semaglutide 0.5 mg and 11,553 CNY with once-weekly semaglutide 1.0 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3593476306
07Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese diabetes model, dulaglutide 1.5 mg had lower projected discounted life expectancy than semaglutide 0.5 mg.
In plain wordsIn computer projections, dulaglutide had lower life expectancy than lower-dose semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDiscounted life expectancy versus lower semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 0.5 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Life expectancy advantage of comparator
0.04 years
semaglutide 0.5 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3593476307
08Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese diabetes model, dulaglutide 1.5 mg had lower projected discounted life expectancy than semaglutide 1.0 mg.
In plain wordsIn computer projections, dulaglutide had lower life expectancy than higher-dose semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDiscounted life expectancy versus higher semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 1.0 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Life expectancy advantage of comparator
0.1 years
semaglutide 1.0 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3593476308
09Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese diabetes model, dulaglutide had lower projected discounted quality-adjusted life expectancy than semaglutide 0.5 mg.
In plain wordsIn computer projections, dulaglutide had lower quality-adjusted life expectancy than lower-dose semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDiscounted quality-adjusted life expectancy versus lower semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 0.5 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Quality-adjusted life expectancy advantage of comparator
0.08 QALYs
semaglutide 0.5 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3593476309
10Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese diabetes model, dulaglutide had lower projected discounted quality-adjusted life expectancy than semaglutide 1.0 mg.
In plain wordsIn computer projections, dulaglutide had lower quality-adjusted life expectancy than higher-dose semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDiscounted quality-adjusted life expectancy versus higher semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 1.0 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Quality-adjusted life expectancy advantage of comparator
0.19 QALYs
semaglutide 1.0 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3593476310
11Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese diabetes model, dulaglutide had higher projected lifetime costs than semaglutide 0.5 mg.
In plain wordsIn computer projections, dulaglutide had higher lifetime costs than lower-dose semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLifetime costs versus lower semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 0.5 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Lifetime savings with comparator
8355 CNY
semaglutide 0.5 mg versus dulaglutide
Source sentences
Summary
Clinical benefits were achieved at reduced costs, with lifetime cost savings of 8355 Chinese Yuan (CNY) with once-weekly semaglutide 0.5 mg and 11,553 CNY with once-weekly semaglutide 1.0 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3593476311
12Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Chinese diabetes model, dulaglutide had projected lifetime costs 11,553 CNY higher than semaglutide 1.0 mg.
In plain wordsIn computer projections, dulaglutide had higher lifetime costs than higher-dose semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLifetime costs versus higher semaglutide dose
Study
n: not reported in source
IHE-DCM
Comparator
Semaglutide 1.0 mg
Outcome group
Healthcare costs and utilization · Whole body
Source sentences
Summary
Clinical benefits were achieved at reduced costs, with lifetime cost savings of 8355 Chinese Yuan (CNY) with once-weekly semaglutide 0.5 mg and 11,553 CNY with once-weekly semaglutide 1.0 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
Compared with dulaglutide 1.5 mg, once-weekly semaglutide 0.5 mg and 1.0 mg were associated with improvements in discounted life expectancy of 0.04 and 0.10 years, respectively, and improvements in discounted quality-adjusted life expectancy of 0.08 and 0.19 quality-adjusted life years (QALYs), respectively.
Summary · context
The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes uncontrolled on metformin in the Chinese setting.
Summary · context
The Swedish Institute of Health Economics Diabetes Cohort Model (IHE-DCM) was used to evaluate the long-term health and economic outcomes of once-weekly semaglutide and dulaglutide.
Summary · context
Analysis was conducted from the perspective of the Chinese healthcare systems over a time horizon of 40 years.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3593476312

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.

Summary

Results from this study12

Studies that did not test the peptide alone12

Version history

Subjects

Publication types

Keywords